Majority of Stockholders Support Pasithea Directors at Special Meeting

by divibasicbldev | Dec 14, 2022 | Press Releases

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central...

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

by divibasicbldev | Dec 12, 2022 | Press Releases

MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central...

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

by divibasicbldev | Dec 6, 2022 | Press Releases

PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory-driven CNS diseasesMIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics...

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

by divibasicbldev | Nov 29, 2022 | Press Releases

MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central...

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

by divibasicbldev | Oct 17, 2022 | Press Releases

Pasithea’s Chairman, Prof. Lawrence Steinman, to be Awarded Honorary Doctorate by University of Buenos AiresMIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...